CD 163: A Specific Immunohistochemical Marker for Acute Myeloid Leukemia with Monocytic Differentiation in Fixed Paraffin Embedded Bone Marrow
Mohammad Mahmoud Abdel Hamid;
Abstract
The hemoglobin-haptoglobin scavenger receptor; CD163 is a monocyte/macrophage-restricted transmembrane protein that is highly sensitive and specific in distinguishing AML with monocytic component from other AML classes.
The interest in this molecule has grown exponentially, since CD163 has been an endocytic receptor selectively expressed in macrophages with preservation of regulation and function after malignant transformation which can be used for leukemic blasts targeting by several substances, for instance DNA and drugs chemically linked to haptoglobin/hemoglobin complexes, so CD163 can be used as a potential, novel, therapeutic target for a subset of patients with AML.
The aim of this work was to apply an additional monocytic-specific immunohistochemical marker; CD163 that may be helpful in the evaluation of AML cases for potential monocytic component
The present work assessed expression of CD163 on leukemic blast cells of 23 newly diagnosed AML patients. All patients were subjected to complete history taking, thorough clinical examination and laboratory investigations including: complete hemogram, bone marrow aspiration with examination of leishman- stained peripheral blood and bone marrow smears, immunophenotyping, trephine biopsy examination by H&E and detection of CD163 by IHC.
The CD163 was positively expressed in 7/10 (70%) cases of the monocytic sub-group of AML patients, and was positive in only 1/13(7.7%) case of the non-monocytic sub-group of AML patients. (P= 0.06)
No significant statistical difference was found between CD163 positive and negative cases regarding demographic, clinical or laboratory variables except for PB blasts and BM blasts, where positive CD136 cases had higher median for PB blasts (50% vs. 30% respectively) and higher median for BM blasts (72.5% vs. 48% respectively).
In conclusion, we found that CD163 is exclusively expressed on the majority of monocytic and a significant subset of myelomonocytic leukemias, suggesting that the restriction of CD163 expression to cells committed to the monocytic lineage is preserved beyond malignant transformation. This lineage-restricted pattern of antigen expression may thus be useful for the immunophenotypic su
The interest in this molecule has grown exponentially, since CD163 has been an endocytic receptor selectively expressed in macrophages with preservation of regulation and function after malignant transformation which can be used for leukemic blasts targeting by several substances, for instance DNA and drugs chemically linked to haptoglobin/hemoglobin complexes, so CD163 can be used as a potential, novel, therapeutic target for a subset of patients with AML.
The aim of this work was to apply an additional monocytic-specific immunohistochemical marker; CD163 that may be helpful in the evaluation of AML cases for potential monocytic component
The present work assessed expression of CD163 on leukemic blast cells of 23 newly diagnosed AML patients. All patients were subjected to complete history taking, thorough clinical examination and laboratory investigations including: complete hemogram, bone marrow aspiration with examination of leishman- stained peripheral blood and bone marrow smears, immunophenotyping, trephine biopsy examination by H&E and detection of CD163 by IHC.
The CD163 was positively expressed in 7/10 (70%) cases of the monocytic sub-group of AML patients, and was positive in only 1/13(7.7%) case of the non-monocytic sub-group of AML patients. (P= 0.06)
No significant statistical difference was found between CD163 positive and negative cases regarding demographic, clinical or laboratory variables except for PB blasts and BM blasts, where positive CD136 cases had higher median for PB blasts (50% vs. 30% respectively) and higher median for BM blasts (72.5% vs. 48% respectively).
In conclusion, we found that CD163 is exclusively expressed on the majority of monocytic and a significant subset of myelomonocytic leukemias, suggesting that the restriction of CD163 expression to cells committed to the monocytic lineage is preserved beyond malignant transformation. This lineage-restricted pattern of antigen expression may thus be useful for the immunophenotypic su
Other data
| Title | CD 163: A Specific Immunohistochemical Marker for Acute Myeloid Leukemia with Monocytic Differentiation in Fixed Paraffin Embedded Bone Marrow | Other Titles | CD163: علامة كيميائية هيستولوجية مناعية محددة للوكيميا النخاعية الحادة مع تباين وحيدي بـالبارافين الثابت حول نقي العظم | Authors | Mohammad Mahmoud Abdel Hamid | Issue Date | 2014 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.